Home » Stocks » Clearside Biomedical

Clearside Biomedical, Inc. (CLSD)

Stock Price: $1.76 USD -0.03 (-1.68%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 78.97M
Revenue (ttm) 6.23M
Net Income (ttm) -18.28M
Shares Out 54.31M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $1.76
Previous Close $1.79
Change ($) -0.03
Change (%) -1.68%
Day's Open 1.78
Day's Range 1.71 - 1.79
Day's Volume 125,242
52-Week Range 0.56 - 4.13

More Stats

Market Cap 78.97M
Enterprise Value 64.06M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 54.31M
Float 29.61M
EPS (basic) -0.45
EPS (diluted) -0.45
FCF / Share -0.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.57M
Short Ratio 5.61
Short % of Float 3.79%
Beta 0.99
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 12.69
PB Ratio 9.57
Revenue 6.23M
Operating Income -17.91M
Net Income -18.28M
Free Cash Flow -17.28M
Net Cash 14.91M
Net Cash / Share 0.33
Gross Margin 34.91%
Operating Margin -287.69%
Profit Margin -293.60%
FCF Margin -277.59%
ROA -35.62%
ROE -137.78%
ROIC -1,151.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 3
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(226.70% upside)
Current: $1.76
Target: 5.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth7143.33%-91.3%-33.65%---
Gross Profit2.170.030.350.52--
Operating Income-30.30-82.95-58.41-25.20-17.64-10.19
Net Income-30.77-82.82-58.98-25.88-17.64-10.19
Shares Outstanding38.1730.7325.3113.112.341.74
Earnings Per Share-0.81-2.69-2.33-1.97-7.54-5.86
Operating Cash Flow-27.07-79.20-51.08-22.71-13.90-9.12
Capital Expenditures-0.03-0.09-0.31--0.03-0.14
Free Cash Flow-27.09-79.29-51.39-22.71-13.93-9.26
Cash & Equivalents22.9641.2438.0083.9920.280.00
Total Debt6.419.988.017.595.98-
Net Cash / Debt16.5531.2629.9976.4114.310.00
Book Value11.1623.6221.4271.66-36.66-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Clearside Biomedical, Inc.
Country United States
Employees 33
CEO George M. Lasezkay

Stock Information

Ticker Symbol CLSD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLSD
IPO Date June 2, 2016


Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.